Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Published:2023-09-02 Issue:17 Volume:149 Page:16191-16201
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Liu Junning,Yang Linfeng,Wei Song,Li Jijiang,Yi Pengsheng

Funder

Bureau of Science and Technology Nanchong City

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-05342-5.pdf

Reference42 articles.

1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401–406. https://doi.org/10.1016/j.jclinepi.2010.07.015

2. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A et al (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57(4):821–829. https://doi.org/10.1016/j.jhep.2012.06.014

3. Casadei-Gardini A, Tada T, Shimose S, Kumada T, Niizeki T, Cascinu S et al (2021) Is atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma superior even to lenvatinib? A matching-adjusted indirect comparison. Target Oncol 16(2):249–254. https://doi.org/10.1007/s11523-021-00803-8

4. Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M et al (2022) Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer 180:9–20. https://doi.org/10.1016/j.ejca.2022.11.017

5. Chen CT, Feng YH, Yen CJ, Chen SC, Lin YT, Lu LC et al (2022) Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. Hepatol Int 16(5):1199–1207. https://doi.org/10.1007/s12072-022-10392-x

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives;Discover Oncology;2024-07-03

2. Comparing Health Insurance-ReimbursedFirst Line Lenvatinib and Self-paid Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma;2024-06-27

3. Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta‑analysis;Oncology Letters;2024-06-26

4. Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta‑analysis;Oncology Letters;2024-06-03

5. Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study;Frontiers in Oncology;2024-02-28